HLB group stocks hit their daily lower limit across the board after liver cancer drug approval by the FDA fell through
HLB’s liver cancer drug candidate rivoceranib did not receive approval from the U.S. Food and Drug Administration (FDA). With issues at the Chinese partner company’s production facility cited as the reason, 7on the morning of month 10day, HLB and related affiliate stocks all hit their daily lower limit.
HLB’s liver cancer drug candidate rivoceranib did not receive approval from the U.S. Food and Drug Administration (FDA). This news reached the market early in the session on 2026year 7month 10day.
The company said the reason for the rejection was a problem at the Chinese partner company’s production facility. It was reported that quality and shipment issues related to the facility affected the approval decision.
7month 10day at 9o’clock 34minutes, HLB was down 1ten-thousand5600won from the previous session. Strong selling pressure appeared early in the session, and HLB and related affiliate stocks plunged sharply.
Several affiliates of the HLB Group and related stocks also plunged in tandem, with some hitting the daily lower limit. Further volatility is expected if trading is suspended or if a separate disclosure is released.
The drug in question is rivoceranib, a candidate compound aimed at treating liver cancer. This setback in securing approval is an issue related to the overall stages of clinical development, manufacturing, and regulatory review.
Any further explanation from the company and its partners, or an official disclosure, is expected to be important information for investors. It will be necessary to check future disclosure details and announcements from the relevant authorities.